Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children.
Pediatrics
; 150(2)2022 08 01.
Статья
в английский
| MEDLINE | ID: covidwho-1865361
ABSTRACT
This report presents 2 pediatric cases of multisystem inflammatory syndrome in children and adults (MIS-C/A) post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination (MIS-V). Both children presented with MIS-V within 6 weeks of receiving their first and only dose of Pfizer-BioNTech's SARS-CoV-2 vaccine. The first patient had symptoms of MIS-C/A with peri-myocarditis and shock, and the second 1 had classic Kawasaki disease features. Both responded well to intravenous immunoglobulins and/or systemic corticosteroids. Both children were positive only for SARS-2-CoV antispike (S) (and not for antinucleocapsid [NC]) antibodies consistent with a postvaccine, and not a postinfection, event. Surveillance for rare adverse events following immunization should continue, especially now that SARS-CoV-2 vaccination is approved in the 5 to 11 year age group that has had the highest risk of developing MIS-C post SARS-CoV-2 infection. Our patients did not receive any further SARS-CoV-2 vaccines. Our report highlights the importance of measuring differentiating antibodies (anti-S and anti-NC) that can be used within a specific timeframe to help determine if a patient has MIS-V post vaccine (only anti-S present), or MIS-C/A post SARS-CoV-2 infection (both anti-S and anti-NC present).
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
COVID-19 Vaccines
/
COVID-19
Тип исследования:
История болезни
/
Наблюдательное исследование
/
Прогностическое исследование
Темы:
Длинный Ковид
/
Вакцина
Пределы темы:
Дети
/
Люди
Язык:
английский
Год:
2022
Тип:
Статья
Аффилированная страна:
Peds.2021-055956
Документы, близкие по теме
MEDLINE
...
LILACS
LIS